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https://doi.org/10.1016/j.jcmgh.2019.02.001SUMMARY
The present review addresses the complex role of carbo-
hydrates (simple and complex) and fats (saturated, unsat-
urated, polyunsaturated) in the pathogenesis of
nonalcoholic fatty liver disease. Specifically the review fo-
cuses on the liver–adipose tissue axis in this disease and the
role each nutrient class plays in the crosstalk between the
liver and the adipose tissue and the pathophysiology of
nonalcoholic fatty liver disease.
Macronutrient metabolism is a highly orchestrated pro-
cess, with adipose tissue and liver each playing central
roles in nutrient uptake, processing, transport, and stor-
age. These 2 tissues form an important metabolic circuit,
particularly as it relates to lipids as the primary storage
form of excess energy. The function of the circuit is influ-
enced by many factors, including the quantity and type of
nutrients consumed and their impact on the overall health
of the tissues. In this review we begin with a brief summary
of the homeostatic disposition of lipids between adipose
tissue and liver and how these processes can become
dysregulated in obesity. We then explore how specific di-
etary nutrients and nutrient combinations can exert
unique influences on the liver–adipose tissue axis. (Cell Mol
Gastroenterol Hepatol 2019;7:749–761; https://doi.org/
10.1016/j.jcmgh.2019.02.001)
Keywords: Carbohydrate; Fat; Metabolism; Diet; Fatty Liver
Disease.
Macronutrient Flux Through Adipose
Tissue and Liver
When a healthy individual consumes dietary fat, the
lipids are converted to triglyceride within the intestine and
packaged into chylomicrons for delivery to peripheral tis-
sues (primarily muscle and adipose tissue) (Figure 1). When
chylomicrons reach their target tissues, fatty acids are
released through the local action of lipoprotein lipase (LPL).
Adipose tissue is reasonably efficient at extracting free fatty
acids (FFA) from chylomicrons for uptake and storage;
however, there is some “spillover” of FFA into the circula-
tion (33%–36% of the total delivered), which then become
available for uptake by the liver.1 The chylomicron rem-
nants that are left after LPL-mediated triglyceride lipolysis
also contain a small proportion of their original triglyceridecontent. Spillover FFA and chylomicron remnants represent
2 routes by which dietary fat can gain direct access to the
liver. Stable isotope studies indicate that in normal in-
dividuals, dietary fat accounts for approximately 15% of the
triglyceride present in the liver at any given time.2
When a healthy individual consumes carbohydrate, any
substrate in excess of that needed to fulfill short-term
metabolic need is converted into fatty acid through de
novo lipogenesis (DNL). DNL takes place in both the liver
and adipose tissue (reviewed in3,4). The fatty acid products
of DNL are esterified into triglyceride for storage; the pri-
mary reservoir for stored lipids is in adipose tissue, and
thus the triglyceride produced in adipose tissue is stored
directly. In the liver, some newly synthesized triglyceride is
stored locally, but most is packaged into very low density
lipoproteins (VLDL) for export to adipose tissue.5 Adipose
tissue extracts lipid from VLDL in the same fashion as it
does from chylomicrons, using LPL. When carbohydrates
and lipids are consumed simultaneously, adipose tissue is
called on to import glucose for DNL and take up lipids from
both chylomicrons and VLDL. Insulin, induced by dietary
carbohydrate, helps adipose tissue accommodate the sub-
strate load by increasing cell-surface expression of the
GLUT4 glucose transporter6 and increasing adipose tissue
LPL activity.7
During fasting, adipose tissue becomes a net exporter
rather than importer of lipid. When nutrients and insulin are
sparse, adipocytes hydrolyze their intracellular triglycerides
using hormone-sensitive lipase and release FFA for uptake
by several tissues including the liver. Indeed, 59% of the
triglyceride in a normal liver derives from FFA taken up
from the circulation.2 In obesity, the situation in adipose
tissue resembles fasting: although insulin levels are
adequate or even high, adipocytes can no longer respond to
the anabolic effects of the hormone, so they instead behave
as though they are insulin-deficient, hydrolyzing intracel-
lular triglyceride and releasing FFA into the circulation. To
Figure 1. Route of dietary carbohydrates and fats to the liver and adipose tissue. Dietary carbohydrate enters the portal
circulation from the intestine and enters the liver. Excess substrate not needed for metabolism is converted to fatty acid via
DNL and incorporated into triglyceride. Triglycerides are exported from the liver as VLDL, where they are delivered to adipose
tissue, where they are broken down into FFA by the enzyme LPL and stored. Dietary fat is packaged into chylomicrons in the
intestine and delivered initially to muscle and adipose tissue. Any lipid remaining in the chylomicron remnants are routed to the
liver, as are “spillover” FFA not taken up by adipocytes. CHO, carbohydrate; TG, triglyceride.
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ability of adipocytes to take up lipid from chylomicrons and
VLDL. This leads to further increases in circulating FFA,
which are then diverted to other tissues including the liver,
where they are stored as ectopic lipid. Overall, alterations in
nutrient flux through the adipose-liver circuit play a key role
in the pathogenesis of fatty liver disease. Dietary carbohy-
drates exert a direct influence on the liver through DNL;
carbohydrates and fats can also contribute indirectly to fatty
liver by increasing adipose tissue lipid stores that are sub-
sequently mobilized through lipolysis.
The adipose tissue–liver metabolic circuit is sensitive not
only to the total amount of calories consumed but also the
distribution of calories across macronutrient classes(carbohydrates and fats) and even to individual types of
macronutrients. The following sections explore the impact
of specific nutrients and nutrient combinations on adipose
tissue and liver health.
The Influence of Obesity on the
Adipose-Liver Axis
Under normal physiological conditions the liver and
adipose tissue strive to maintain metabolic homeostasis
through the secretion of adipokines and growth factors.8,9
Under conditions of nutrient excess this communication is
disrupted, contributing to metabolic derangement and
related injury to both organs.
2019 Macronutrients and the Adipose-Liver Axis 751Looking first at adipose tissue, obesity prompts an in-
crease in tissue mass through a combination of adipocyte
hypertrophy and hyperplasia. This enlargement increases
oxygen consumption and strains oxygen delivery to the
tissue,10,11 which results in cell death and the associated
recruitment of inflammatory cells from the circulation.12-14
Diseased adipocytes also undergo changes in adipokine
production: for example, adiponectin, which promotes
physiological lipid storage in fat and lipid oxidation in
muscle and liver, is significantly decreased in obesity.15 In
contrast, inflammatory cytokines and chemokines, such as
tumor necrosis factor, interleukin-6, monocyte chemo-
attractant protein-1 (CCL2), and others, are produced in
increased amounts by adipocytes (reviewed in8).16-20 Tu-
mor necrosis factor and interleukin-6 impair responsiveness
to insulin.21,22 This interferes with the ability of adipocytes
to take up fatty acids from the circulation, and furthermore
induces the hydrolysis of intracellular triglycerides, which
leads to the systemic release of more fatty acids. Cytokines
also promote the recruitment of inflammatory cells to adi-
pose tissue, which inflict further damage, thus perpetuating
adipose tissue dysfunction.20,23,24 Overall, the dysregulation
of metabolic and immunoregulatory adipokines in
dysfunctional adipose tissue results in the rerouting of fatty
acids to other “ectopic” tissues, including the liver.
The principal compound secreted by the liver that in-
fluences the adipose-liver axis is fibroblast growth factor-21
(FGF21). FGF21, produced by hepatocytes, promotes
glucose uptake and energy expenditure in white adipose
tissue.25 In response to FGF21, adipose tissue secretes adi-
ponectin, which then circles back to the liver to facilitate
insulin signaling.26 In obesity, hepatic production of FGF21
is upregulated.9 Its action toward white adipose tissue,
however, is blunted.27 FGF21 rises even further with the
development and progression of hepatic steatosis,28,29
underscoring how obesity interferes with another funda-
mental circuit intended to maintain metabolic homeostasis.
The Influence of Specific Dietary
Macronutrients on the Liver and
Adipose Tissue
It is well established that consumption of excess calories
is a major factor in the development of obesity and fatty
liver disease, particularly when coupled with genetic pre-
dispositions and a sedentary lifestyle. There is also infor-
mation indicating that the composition of a diet,
independent of its caloric content, can exert a unique in-
fluence on the well-being and function of adipose tissue and
liver. In this section we highlight the role of macronutrients
in nonalcoholic fatty liver disease (NAFLD) pathogenesis,
paying particular attention to their effect on adipose-liver
interactions. The discussion is organized by macronutrient
class, specifically highlighting carbohydrates and fats.
Although we focus on macronutrients 1 group at a time, it is
important to keep in mind that the human diet constitutes a
mixture of carbohydrates, fats, and proteins. The standard
human diet comprises 40%–50% carbohydrate, 30%–40%
fat, and 20% protein. The interactions among macronutrientclasses can themselves be biologically important, and we
highlight these in select cases.Dietary Carbohydrates
Carbohydrates are designated as simple or complex based
on the number of sugar molecules they contain (mono-
saccharides and disaccharides vs polysaccharides). Individual
carbohydratesdiffer in their abilities to induceDNL,30-32which
plays a role in their tendency to provoke fatty liver and more
serious forms of liver injury. Numerous studies have investi-
gated the role of dietary carbohydrates in NAFLD pathogen-
esis. Less information is available on the role of dietary
carbohydrates on adipose tissue in the context of NAFLD.
Simple Carbohydrates. Simple carbohydrates (sugars)
include the dietary sweeteners glucose, fructose, and sucrose.
Glucose and fructose are monosaccharides, whereas sucrose
is a disaccharide comprised of glucose and fructose. Glucose
and fructose are readily absorbed by the small intestine. Until
recently, both molecules were believed to be transported
directly from the intestine to the portal circulation for
delivery to the liver; however, new evidence indicates that
fructose is metabolized by the intestine and enters the portal
circulation only when consumed in amounts sufficient to
saturate this metabolic capacity.33 Glucose and fructose
molecules that do make their way into the portal circulation
are taken up by the liver. Both sugars stimulate DNL, which
under conditions of excess can lead to hepatic steatosis.
Importantly, the DNL reaction yields palmitate, a toxic long-
chain saturated fatty acid (SFA); once generated, palmitate
must be promptly desaturated and incorporated into tri-
glyceride, or it can cause hepatocellular injury (discussed in
the saturated fat section). Fructose is a potent inducer of DNL
because of the lack of feedback regulation of its metabolism
by fructokinase (reviewed in 34). Fructose metabolism stim-
ulates more hepatic lipid production than glucose; it also
consumes ATP and generates uric acid as a by-product.35
Furthermore, fructose metabolism yields toxic carbonyls
that can damage mitochondria.36 This combination of events,
combined with the generation of SFA, can lead to liver injury
through endoplasmic reticulum (ER) stress and hepatic
mitochondrial dysfunction.37-40 The heightened toxicity of
fructose compared with glucose has been demonstrated in
multiple studies involving animals and humans. Work from
our laboratory showed that fructose, when used as the car-
bohydrate in a methionine-choline-deficient diet, induced
twice the degree of liver injury than glucose.41 Others found
that in mice fed a high-fat diet, fructose rather than glucose in
the drinking water led to more microvesicular hepatic stea-
tosis and more activation of the stress kinase Jun N-terminal
kinase in the liver, which are both predictors of greater liver
injury.42 In human subjects, consumption of fructose-
sweetened beverages but not glucose-sweetened beverages
for 10 weeks induced mild liver injury as evidenced by
elevated serum g-glutamyl transpeptidase along with eleva-
tions in several circulating inflammatory molecules.43,44
Furthermore, epidemiologic studies confirm that long-term
fructose consumption is associated with serious hepatic
outcomes including steatohepatitis and liver fibrosis.45-47
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liver, fructose can also be used by other organs including
adipose tissue. Studies of adipocytes in culture show that
fructose, but not glucose, has a trophic effect on the cells,
stimulating the expansion of adipocyte precursors.48 Not
surprisingly, fructose metabolism by adipocytes also pro-
motes lipogenesis, leading to storage of some of the fatty
acids and the release of some as FFA.49 Studies have shown
that fructose, but not glucose, consumption causes insulin
resistance.32,42 This acts as an ongoing stimulus to lipolysis
in fructose-exposed adipose tissue. Moreover, the uric acid
produced during fructose metabolism can inflict damage on
adipocytes, stimulating oxidant stress and the production of
inflammatory cytokines.50,51 Overall, the adverse effects of
fructose on adipocytes compound its adverse effects on the
liver, by causing adipose inflammation and preventing
proper adipose tissue lipid storage resulting in diversion of
fatty acids to the liver (Figure 2).
The effects of glucose on liver and adipose tissue are
generally milder than fructose, although overconsumption
of glucose is not without consequence. Like fructose, glucose
promotes DNL, which yields SFAs that are esterified and
stored in adipose tissue and liver. Studies in mice indicate
that glucose and fructose induce similar degrees of hepatic
lipid accumulation when incorporated into isocaloric
diets.41,42 Similarly in humans, when identical amounts of
glucose or fructose are fed to human subjects for periods up
to 4 weeks, both sugars induce comparable increases in
liver fat content.52-54 Because the lipogenic properties of
glucose and fructose seem similar, the increased harm from
fructose in humans is likely related to ATP depletion and
uric acid production and their downstream consequences.
One important point to note about dietary sugars is that
their ability to induce liver injury is modulated by the fat
present in the diet. Specifically, saturated fat induces DNL
independently of dietary sugar,55 so when sugar and satu-
rated fat are consumed together, the DNL effect is magnified.
This synergy is most evident when sugar (as the DNL sub-
strate) is highly abundant in the diet. Our group showed
that sugar þ saturated fat, when fed to mice in a ratio of
60:20, induced significantly more DNL, hepatic steatosis,
and liver injury than an equivalent combination of sugar þ
unsaturated fat.56,57 This synergy was not seen when
sugar þ saturated fat were fed in a ratio of 40:40.58
Complex Carbohydrates. Complex carbohydrates
(starches, glucans, fructans, and cellulose) are poly-
saccharides with a range of structures and physical proper-
ties. Glucans, fructans, and cellulose, along with a subset of
starches that are highly resistant to enzymatic digestion, are
often grouped into a single category under the term “dietary
fiber.” The impact of starches and fiber on adipose tissue and
liver is dependent in part on theirmetabolism by the host, but
also on their metabolism by microbes residing in the gut.
Starches. Starches are polymers of glucose with different
chain lengths and a-glycosidic linkages. Like all poly-
saccharides, they require enzymatic digestion before ab-
sorption. However, because of their size and structure they
are not completely degraded to monosaccharides or
disaccharides in the small intestine and as a result are less“glycemic” than simple sugars. Because starch yields lower
blood concentrations of glucose than sugar, it is less likely to
stimulate lipogenic genes in the liver; furthermore, it pro-
vides less substrate for fatty acid synthesis. The blunted
lipogenic effect of dietary starch compared with sugar has
been demonstrated in direct comparisons of the 2 carbo-
hydrates in mice.59 Even within the category of dietary
starches there are variations in the ability of individual
polysaccharides to stimulate hepatic lipogenesis depending
on the ease with which they are digested.60 The impact of
high-glycemic (digestible) and low-glycemic (resistant)
starches on adipose tissue have also been investigated in
select studies.61,62 As expected, high-glycemic starches
induced more adipose tissue enlargement than low-
glycemic starches. At present there is little information
available about the effect of dietary starches on adipose
tissue inflammation.
Fiber. Fiber is either very resistant to enzymatic digestion
in the intestine, or in the case of b-linked plant poly-
saccharides (b-glucans and cellulose), cannot be digested at
all by the intestine. These resistant polysaccharides make
their way to the colon, where they undergo fermentation by
colonic bacteria.63 Fermentation of fiber yields the short-
chain fatty acids acetate, butyrate and propionate; some of
these are used by the bacteria themselves, but some are also
absorbed into the portal circulation where they have im-
mediate access to the liver.64 Hepatic extraction of short-
chain fatty acids is efficient but incomplete. This enables
some fatty acids to enter the systemic circulation65 where
they can exert independent influences on adipose tissue.
Focusing on the liver first, it is important to note that short-
chain fatty acids have several effects on hepatic metabolism
that can either promote or prevent NAFLD. Butyrate stim-
ulates fatty acid oxidation and thus should be beneficial to
the liver.66 In contrast, acetate is a substrate for hepatic
lipogenesis67 and propionate stimulates gluconeogenesis,68
which should have an overall adverse effect. A recent
mouse study disputes the prospect of harm by demon-
strating that supplemental short-chain fatty acids prevent,
rather than promote, experimental fatty liver disease.69
Overall it remains unclear whether the net effect of short-
chain fatty acids on the liver is beneficial or detrimental in
the pathogenesis of NAFLD, although experts are leaning
toward a salutary role for these compounds.70 With respect
to adipose tissue, short-chain fatty acids are believed
beneficial to metabolic homeostasis. Animals and cell cul-
ture studies demonstrate that short-chain fatty acids pro-
mote adipocyte development and fat accumulation,
stimulate adipokine production, and decrease lipolysis.71-74
Human studies, although correlative, indicate that diets that
increase circulating levels of short-chain fatty acids also
reduce systemic circulating fatty acid concentrations, sug-
gesting a suppressive effect on adipose tissue lipolysis.75Dietary Fats
Dietary fats are consumed largely as triglycerides. Fats
are named for the dominant type of fatty acid within the
triglyceride molecule: SFAs, monounsaturated fatty acids
Figure 2. Endocrine
interactions between
liver and adipose tissue
and the influence of
macronutrients. Under
conditions of dietary
excess/obesity, adipose
tissue adiponectin pro-
duction declines and
several proinflammatory
cytokines and chemokines
are upregulated. This can
promote inflammation and
insulin resistance in both
tissues. FGF21 is upregu-
lated in the liver, but its
action is inhibited, pre-
venting energy expendi-
ture in adipose tissue and
promoting lipolysis. The
general contribution of in-
dividual macronutrients to
the dysfunction of adipose
tissue and liver in obesity
and NAFLD is shown
schematically (see text for
details). CHO, carbohy-
drate; IL, interleukin; TNF,
tumor necrosis factor.
2019 Macronutrients and the Adipose-Liver Axis 753(MUFA) or polyunsaturated fatty acids (PUFA). Dietary fat is
taken up by tissues in the form of fatty acids after lipolysis
of triglycerides at the cell surface. Fats are primarily
incorporated into adipose tissue; they have secondary ac-
cess to the liver via chylomicron remnants or spillover of
excess FFAs into the circulation (Figure 1). The biologic
effects of dietary fats are attributable to their componentfatty acids, which are the main focus of the following
summary.
Saturated Fats. Saturated fats and their component SFA
come primarily from animal sources (meat and dairy). The
SFA present in these foods are typically long-chain species
containing 16 or more carbon atoms. Long-chain SFA are
considered the most harmful of dietary fats because they
Table 1.Types of Monounsaturated Fatty Acid Used in Individual Animal and Human Studies
Reference Author Species Dietary monounsaturated fatty acid Notes
58 Duwaerts et al Animal High-oleate sunflower oil
111 Hoefel et al Animal Olive oil
112 Sampath et al Animal Triolein
113 Meneses et al Human Olive oil–enriched mayonnaise, nuts LIPGENE Study
114 Bozzetto et al Human Olive oil
115 Ryan et al Human Olive oil, nuts, olives, fish Mediterranean
116 Properzi et al Human Olive oil, nuts, fish Mediterranean
754 Duwaerts and Maher Cellular and Molecular Gastroenterology and Hepatology Vol. 7, No. 4have toxic effects on many types of cells; this is in contrast
to medium-chain SFA, which are more inert and can even be
beneficial to metabolic health.76,77 Although medium-chain
SFA are less toxic than long-chain SFA they are only minor
components of standard meat and dairy items. However,
they are enriched in a limited number of natural foods, such
as coconut and palm kernel oils. Focusing on long-chain SFA
because of their prevalence in the standard human diet,
these SFA can directly injure hepatocytes through a variety
of mechanisms including death receptor signaling, the
induction of ER stress leading to intrinsic mitochondrial
apoptosis, stimulation of toll-like receptors, activation of
inflammasomes, and impairment of autophagy (reviewed
in78).79-88 SFA are also detrimental to adipocytes. They
enhance adipocyte oxygen consumption, which contributes
to adipose tissue hypoxia in vivo,10,11,89 and in similar
fashion to hepatocytes they cause ER stress, activation of
toll-like receptor and nuclear factor-kB, which results in
cell death and the production of proinflammatory
cytokines.90-97 The adverse effects of SFA-enriched diets on
liver and adipose tissue have been documented in many
studies in experimental animals.11,88,98-102 In contrast,
relatively few research groups have challenged human
subjects with saturated-fat diets in the context of a
controlled clinical trial. The available data from short-term
human studies comparing dietary saturated fats with poly-
unsaturated fats indicate that saturated fats have a greater
tendency to induce insulin resistance, hepatic steatosis, and
a proinflammatory state characterized by elevated serum
concentrations of tumor necrosis factor and interleukin-1-
receptor antagonist.103-106
Although there is little doubt that SFA are cytotoxic, the
toxicity of SFA toward liver cells in vivo seems dependent on
their origin from the diet or DNL. This observation comes from
studies from our laboratory investigating the hepatotoxicity of
different combinations of dietary sugars and fats in mice. We
reported that dietary tripalmitin, despite being comprised
exclusively of SFA, caused only mild liver injury unless paired
with sucrose.56 This suggests thatDNLSFA aremore toxic than
dietary SFA, which corroborates evidence in humans that fatty
liver disease is related to excessive DNL.2,107
Unsaturated Fats. Unsaturated fats, which compriseMUFA
and PUFA species, are the principal fats present in plants,
seeds, nuts, and fish. The dominant dietary MUFA is oleic acid,
which is abundant in olive oil. The dominant dietary PUFAs are
linoleic acid (u-6 PUFA) anda-linolenic acid (u-3 PUFA) foundin seeds and vegetables; other important dietary u-3 PUFAs
are the very long chain species eicosapentaenoic acid and
docosahexaenoic acid, which can be produced froma-linolenic
acid or obtained directly from a diet containing fish.108 In
general, unsaturated fats are considered healthier than satu-
rated fats for the liver and adipose tissue. Still, there are
properties that distinguish MUFA from PUFA, so the 2 classes
are summarized individually.
Monounsaturated Fatty Acid. MUFA, unlike SFA, exert
little toxicity toward liver or adipose tissue
cells.84,88,91,97,109,110 In fact, MUFA have been reported to
promote adipocyte hyperplasia rather than the less desir-
able cellular enlargement in vivo, in association with
blunted expression of inflammasome components and acti-
vation of metabolic pathways that portend improved insulin
sensitivity.99 Interestingly, despite the apparently benign
nature of dietary MUFA toward hepatocytes and adipocytes
in vitro, some studies indicate that MUFA-enriched diets
(see Table 1 for ingredients) induce more hepatic steatosis
than isocaloric SFA-enriched diets.58,111,112 Pertinent to this
point, studies from our laboratory showed that mice fed
diets containing 40% kcal MUFA in the form of high-oleate
sunflower oil for 6 months developed substantial hepatic
steatosis coincident with pronounced adipose tissue injury
and inflammation.58 In 1 human study, feeding a high con-
centration of MUFA (44% kcal) for 12 weeks also induced
monocyte chemoattractant protein-1 expression in adipose
tissue.113 This raises questions as to whether MUFA are
truly nontoxic in vivo, particularly when used in high con-
centrations in the diet. In humans with NAFLD, the effects of
MUFA-enriched “Mediterranean” diets have been explored
in a small number of carefully controlled clinical trials. In 2
studies, subjects were fed a MUFA-enriched diet (40% total
kcal fat) or a lower-fat nonenriched diet (30% total kcal fat)
for 6–8 weeks.114,115 In both cases the MUFA-enriched diet
substantially reduced hepatic steatosis and improved insu-
lin sensitivity more than the comparison diet, but other
measures were equivalent. A third study was recently
published that tested similar diets for 12 weeks. Unlike the
earlier studies, this one showed improvement in hepatic
steatosis with both the MUFA-enriched diet and the low-fat
diet, with no significant difference between the 2.116 Experts
are now calling for further investigation of MUFA-enriched
diets in patients with NAFLD that include extended treat-
ment intervals and robust liver and adipose tissue outcome
measures.117 One important caveat is that Mediterranean
2019 Macronutrients and the Adipose-Liver Axis 755diets, although enriched in MUFA, may also contain higher
levels of PUFA than comparison diets. This can make it
difficult to assign any benefit of a Mediterranean diet spe-
cifically to MUFA. Until further evidence is collected, the
specific benefit of MUFA for metabolic health remains
uncertain.
Polyunsaturated Fatty Acid. PUFA are generally char-
acterized as beneficial to metabolic health, particularly in
relation to SFA. PUFA, however, are divided into 2 major
subspecies (u-3 and u-6 PUFA) that can have different effects
on tissue biology. For example, u-3 PUFA can suppress
inflammation through the generation of specialized pro-
resolving mediators,118 whereas u-6 PUFA can promote
inflammation by conversion to arachidonic acid and other
inflammatory eicosanoids119 (reviewed in120). The average
Western diet contains far less u-3 PUFA than u-6
PUFA.108,120,121 Consequently, efforts are underway to
encourage incorporation of more u-3 PUFA into the diet or
the use of u-3 PUFA supplements, or both.121 Among the
beneficial effects of PUFA, regardless of subspecies, are their
ability to suppress lipogenesis and stimulate fatty acid
oxidation by downregulating sterol regulatory element-
binding protein-1, carbohydrate-responsive element-binding
protein, and farnesoid X receptor and activating peroxisome
proliferator-activated receptor-a.122-125 In addition, u-3 and
u-6 PUFA have both been shown to suppress nuclear factor-
kB, inflammasome activation, and promote autophagy in he-
patocytes.126,127 Similarly, u-3 and u-6 PUFA are both
capable of suppressing adipocyte hypertrophy and prevent-
ing inflammation and fibrosis in adipose tissue,91,95,128,129
although there may be some selective benefit of u-3 over
u-6 PUFA.129 In a study of mice in vivo, u-3 PUFA supple-
mentation could prevent and reverse high-fat diet-induced
hepatic steatosis.130 Although in another study u-6 PUFA did
not achieve the same reduction in liver fat,100 u-3 and u-6
PUFA both seem capable of preventing diet-induced insulin
resistance and avoiding the diet-induced ER stress and in-
flammatory changes in the liver that occur with SFA-enriched
diets.100,130 In humans, some trials have compared PUFA-
enriched diets (u-3 or u-6) with diets with other
fats,113,131,132 but many more have evaluated the effects of
u-3 PUFA supplements on subjects with fatty liver disease.
The results of these trials are elegantly summarized in 2
recent reviews.108,121 The consensus opinion is that although
some studies report an advantage of u-3 PUFA supplemen-
tation, overall outcomes are variable, and the promise of a
therapeutic benefit is dampened by safety concerns related to
bleeding and interactions with anticoagulant medications.
Until further studies can verify the efficacy of u-3 PUFA
supplements as a therapeutic for NAFLD, experts still
recommend incorporating more u-3 PUFA into the diet in the
form of fish and seafood to maintain or improve metabolic
health.Conclusions
Overnutrition in any form poses a risk for obesity
and fatty liver disease. The specific consequences ofovernutrition on adipose tissue and liver, however, depend
not only on the amount of energy consumed but also on
the type and distribution of macronutrients that make up
the diet. Carefully controlled experiments dissecting the
impact of individual macronutrients on adipose tissue
and liver have enabled their placement into a general
rank order on the spectrum of harmful-to-benign. For
carbohydrates this is fructose > glucose > starch > fiber,
based primarily on their bioavailability to and metabolism
within the liver, and for fats the rank is saturated
 monounsaturated > polyunsaturated, based on their
ability to induce cytotoxicity and their potential to
regulate DNL and fatty acid oxidation. The challenge is
how to translate the information gained from these
experimental studies to real-world situations in which di-
ets are complex and ever-changing. As nutritional research
continues, these challenges can be addressed, culminating
in the development of sound nutritional guidelines for
metabolic health.References
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